Along with discussing different kinds of RNA therapeutics that can be used against ARDS, the authors also indicated prospective targets, which included mediators involved in (i) reducing vascular permeability (Claudin-4, angiopoietin), (ii) reducing inflammation and cell death (MIP-2, Caspase-3, IL-6, HIPK1, S1P, Rip2, NF-kB, MTOR), and (iii) resolving inflammation and tissue repair (by the use of RNAi for upregulation of regulatory T cells (TF-foxp3), induction of IL-10 secretion by T cells). This evidence concerns the gene IL6 and acute respiratory distress syndrome.